Kalaris Q2 2026 net loss $11.5M; cash $93.5M funds operations into Q4 2027

Kalaris Therapeutics, Inc.

Net loss $11.5M for Q2 2026 vs $11.4M in Q2 2025; R&D expense $9.0M (up from $8.4M).
Cash, equivalents and marketable securities $93.5M as of June 30, 2026, down from $118.0M at Dec 31, 2025.
Phase 1b/2 TH103 study dosing ongoing; preliminary data expected 1H 2027; Phase 3 start on track for year-end 2027.
Expanded Phase 1a data released, reinforcing BCVA, OCT, pharmacokinetic and time-to-retreatment findings.
Leadership additions: Liisa Bayko as CFO (from Evercore ISI) and Laurie Keating to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.